Pharma BD Deal Intelligence
A $2.1 billion licensing deal that hands Novo Nordisk global rights to Vivtex's oral drug-delivery platform for peptide-based obesity and diabetes therapies. The move hedges Novo's injectable franchise against looming semaglutide generics, though the payout structure remains almost entirely milestone-and-royalty rather than guaranteed cash.
Days after suffering a heavy blow in the clinic, Novo Nordisk is standing its ground in the obesity market, linking up with Boston's Vivtex to advance novel…
Novo Nordisk is licensing select Vivtex oral drug delivery technologies in a deal that commits up to $2.1 billion to the startup, the companies announced…
Novo Nordisk strikes $2.1B oral obesity biologic deal with Vivtex; platform enables oral delivery of peptide therapeutics for weight management
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
On February 25, 2026, Novo Nordisk and Vivtex Corporation (an MIT/Robert Langer-founded biotech) announced a global technology licensing partnership to develop next-generation ORAL biologic medicines for obesity, type 2 diabetes and associated metabolic comorbidities. Vivtex licenses its proprietary GI-ORIS gastrointestinal screening and oral drug-delivery platform - which pairs physiologically relevant GI assays with AI/computational modeling to optimize oral bioavailability of peptide and protein therapeutics traditionally limited to injection. Vivtex is eligible for an undisclosed upfront payment plus research funding, development and commercial milestones totaling up to $2.1 billion, and tiered royalties on future net sales; Novo Nordisk assumes global development, manufacturing, regulatory and commercialization responsibility. The deal extends Novo's oral-obesity strategy amid looming semaglutide generics and the CagriSema setback.
100M US cases/yr · $50.0B US Obesity Rx Market (2025)
Oral formulations of GLP-1 and other peptide therapeutics for obesity are a major competitive frontier. Novo's oral semaglutide (Rybelsus) showed the potential but oral bioavailability remains challenging. Vivtex platform aims to improve oral delivery of biologic obesity drugs.
Vivtex proprietary technology targets improved oral bioavailability for peptide/protein therapeutics. No specific candidates disclosed. Competes with oral semaglutide (Rybelsus/Wegovy oral), oral orforglipron (Lilly), and danuglipron (Pfizer, discontinued).
Novo partnered with Vivtex for oral biologic delivery technology in obesity/diabetes. Up to $2.1B in milestones.
Deal closed Feb 2026. Combines Novo peptide expertise with Vivtex GI screening platform. Preclinical stage.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Vivtex Inc. (this deal) | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 58 |
← Browse all deals · How we score deals
More: 2026 deals · Novo Nordisk A/S deals · Metabolic deals